Rinderon A Brand names, Rinderon A Analogs
Rinderon A Brand Names Mixture
- Lotrisone (betamethasone + clotrimazole)
Rinderon A Chemical_Formula
Rinderon A RX_link
Rinderon A fda sheet
Rinderon A msds (material safety sheet)
Rinderon A Synthesis Reference
Taub et al., J. Am. Chem. Soc. 80, 4435 (1958)
Rinderon A Molecular Weight
Rinderon A Melting Point
Rinderon A H2O Solubility
Rinderon A State
Rinderon A LogP
Rinderon A Dosage Forms
Oral Solution; Tablet; Solution for Injection; Injectable Suspension; Cream; Gel; Ointment; Foam; Lotion
Rinderon A Indication
Topical use (cream, lotion and ointment): for relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses
Topical use (foam): relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses of the scalp
Systemic use: for the treatment of edocrine disorders, rheumatic disorders, collagen diseases, dermatological diseases, allergic states, ophthalmic diseases, respiratory diseases, hematologic disorders, neoplastic diseases, edematous states, gastrointestinal diseases, tuberculous meningitis and trichinosis.
Rinderon A Pharmacology
Betamethasone and its derivatives, betamethasone sodium phosphate and betamethasone acetate, are synthetic glucocorticoids. Used for its antiinflammatory or immunosuppressive properties, betamethasone is combined with a mineralocorticoid to manage adrenal insufficiency and is used in the form of betamethasone benzoate, betamethasone dipropionate, or betamethasone valerate for the treatment of inflammation due to corticosteroid-responsive dermatoses. Betamethasone and clotrimazole are used together to treat cutaneous tinea infections.
Rinderon A Absorption
Minimal if applied topically.
Rinderon A side effects and Toxicity
Symptoms of overdose include burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, skin atrophy, striae, and miliaria.
Rinderon A Patient Information
Patients using topical corticosteroids should receive the following information and instructions. This information
is intended to aid in the safe and effective use of this medication. It is not a disclosure of all possible adverse
or intended effects.
1. This medication is to be used as directed by the physician and should not be used longer than the prescribed
time period. It is for external use only. Avoid contact with the eyes.
2. Patients should be advised not to use this medication for any disorder other than that for which it was
3. The treated skin area should not be bandaged or otherwise covered or wrapped as to be occlusive.
4. Patients should report any signs of local adverse reactions.
5. Other corticosteroid-containing products should not be used with DIPROLENE AF Cream without first talking to
Rinderon A Organisms Affected
Humans and other mammals